Prostate exposure apparatus

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to prostate exposure apparatuses. The prostate exposure apparatus comprises a bevelled end hollow cylindrical body for the contact of its tip with an exposure area; the tip of the apparatus adjoins a laser source, a heating element, a temperature sensing element, an active electrode, and an indifferent electrode, an electronic unit, an inductor coil, and an ultrasonic assembly representing a piezoelectric radiator with an ultrasound concentrator in the form of a metal core that is an active electrode simultaneously; one end of the active electrode is led on the tip of the apparatus, while the other end is mechanically coupled with the piezoelectric radiator and connected to the electronic unit; the indifferent electrode also connected to the electronic unit is brought out of the body, while the inductor coil is configured so that the active electrode extends along an axis of symmetry; the piezoelectric radiator, targeted laser source, heating element, temperature sensing element and inductor coil are connected to the electronic unit.

EFFECT: due to the inductor coil and ultrasound emitter, the apparatus as compared to its prototype enables additional ultrasonic and magnetic field exposure on the prostate that improves the therapeutic effectiveness.

1 dwg

 

The invention relates to medical equipment, namely to devices for stimulation of the prostate gland (PI). Can be used for the treatment of lesions of the internal cavities of the body.

A device for influencing mud [Rabinski V.S. and other Direct stimulation of the prostate gland in chronic prostatitis. - Journal "Urology and Nephrology", M, 1983, p.4]. This device contains active and indifferent electrodes connected to a device that generates electrical impulses.

A disadvantage of this device is that it enables only one therapeutic function - stimulation.

It is also known a device for influencing mud [Reference assistant. Ed. Annabanana. - M.: Medicine, 1976], consisting of apparatus UDL-350 and special shaped metal Nickel-plated or chrome-plated electrodes, one of which is active.

However, this device has a low therapeutic efficacy due to the fact that it can only perform one procedure - treatment of alternating current.

It is also known a device for influencing mud [Bolin VA, Erusin A.I., Nikitina MV Light laser therapy. A guide for physicians. - Tver: LLC "Publishing house "Triad", 2004. - 206 p] ALTIS-Synchro-02 "Yar". This device contains the device, pre the excitation power supply and remote control, and peripheral devices-plate electrodes indifferent, catheter-electrode urological ESCO No. 2, catheter-rectal electrode, the probe pulse, the probe-emitter pulsed infrared laser, interchangeable fiber optic cable channels infrared continuous laser and a continuous red laser.

However, this device has a low therapeutic efficacy due to the fact that only provides three types of effects of red and infrared radiation and electrical stimulation.

The closest is the device for influencing mud, taken as a prototype, described in the patent [RU, patent 2057557, CL 61N 5/06, 1996]. The device contains a means of physical therapy effects, consisting of the active electrode made in the form of a metal tube, heater, made in the form of nichrome spiral wound on the outer surface of the active electrode and elektroshlifovalnaya from electrode using acrylic-oxide, directional fiber, removable Dildo with a vibrator, and the vibrator is placed inside the tube of the active electrode and is made in the form of a metallic rod, the working end of which has a radius of not less than 0.5 mm, control means, comprising a light guide for observation of the image with a regular structure with eyepiece and source podshock is, and thermocouple. In addition, the device contains indifferently electrode, the generator electromagneto connected with indifferentism and active electrodes, a source of optical radiation, optically coupled with the directional light guide, regulated power supply connected to the heater aspirator with locations in prostatic Department of the urethra. Inside the housing is fixedly mounted an active electrode, a directional fiber, heater, thermocouple and fiber with a regular structure.

The device allows you to search the lesion inside the cavity, the constant visual observation of the object impacts the measurement of its electrical resistance and temperature, exposure to electric signals, low-frequency mechanical vibrations, laser radiation, to fence secret, irrigation, drugs and rinse solutions.

However, the device does not allow for the impact of such important physiotherapeutic factors such as magnetic field and ultrasonic vibrations, which reduces the effectiveness of the treatment.

Object of the invention is a device for influencing mud with a higher therapeutic efficacy.

This is achieved in that in a device for influencing mud containing the first cylindrical body with a beveled end for contacting its working end with the impact zone, located near the working end of the device, the source of laser irradiation, a heating element and a temperature sensor, an active electrode and an indifferent electrode, introduced the electronic unit, the inductor and the ultrasonic emitter consisting of a system with concentrator of ultrasonic vibrations, made in the form of a metal rod and at the same time being an active electrode at one end of the active electrode placed on the working face of the device, and a second end mechanically connected to the system and connected to the electronic module, the indifferent electrode is also connected to the electronic unit, is located outside the housing, and the inductor is designed so that the active electrode passes through it the axis of symmetry, and the system aimed the laser light source, a heating element, a sensor and an inductor connected to the electronic module.

The drawing shows the proposed device, which contains a hollow body 1 with a beveled end for contacting its working end with the impact zone, located near the working end of the light guide device 2, is mechanically coupled to the laser light source 3, an inductor 4, a source of ultrasonic vibrations, which represents a system with 5 mechanically attached conc what ntration ultrasonic vibrations 6, which is also active electrodom, the indifferent electrode 7, the heating element 8, the temperature sensor 9 and the electronic unit 10, with one end of the active electrode 6 made in the form set inside a metal rod that is placed on the working face of the device, and a second end mechanically connected to the system 5 and is connected to the electronic module 10, the indifferent electrode 7 is connected to the electronic module 10, is located outside the housing 1, and the inductor 4 is designed so that the active electrode 6 passes through its axis of symmetry, and the system 5, the laser light source 3 the heater element 8, the temperature sensor 9 is also connected to the electronic module 10. The electronic unit contains the power supply, the control unit and display.

The device may have a microprocessor control.

The device operates as follows. The housing 1 of the device for influencing mud washed with warm water and wipe with alcohol. Then case 1 grease sterile vaseline or glycerine and slow rotational movements injected into the cavity when the phone is turned off, fix the position of the cylindrical body 1, and then include the device in the network and on the Board of the electronic unit 10 set the required parameters physiotherapy treatment (who is Astia, type, intensity, frequency). Press the start button, and then the electronic unit 10 starts to give control signals according to the display parameters, determining one of the following operating modes of the device.

1. The mode of ultrasonic influence.

The signal from the electronic unit 10 is supplied to the system 5, the ultrasonic radiation which affects the object through the hub 6.

2. The mode of stimulation.

The electrical signal from the electronic unit 10 is fed between the active electrode 6 and the indifferent electrode 7 by electrical stimulation of affected object.

3. Mode magnitokontaktnye.

The coil 4 is supplied with electric current of predetermined parameters, which flows through the coils of the coil, it creates a working end of the cylindrical housing 1 of a magnetic field acting on the object. The magnetic field may have a variable and a fixed component of tension depending on the kind of the current flowing in the inductor. Thus, it is possible to set the exposure to an alternating magnetic field, the influence of the static magnetic field or the impact of constant and variable magnetic fields simultaneously.

4. Mode laser exposure.

At the signal, the electronic unit 10 includes a laser light source 3, the beam which is transmitted through n is the identification of the optical fiber 2 to the working end of the cylindrical body 1 and, slucas it comes to the subject of the impact.

5. Mode temperature effects.

The heating element 8 is supplied with electric current from the electronic unit 10 and performs the heating of the working end of the device. All modes can be used simultaneously.

To assess the condition PJ additionally produce a measurement of the temperature of its surface using a sensor 9. When measuring the temperature signals from the temperature sensor 9 is fed to the electronic control unit 10, in which, after signal processing is highlighted code given parameter on the scoreboard.

The duration of the procedures and their number are chosen depending on the symptoms of the disease, the patient depending on the type of oral exposure. Upon termination, the case is removed from the cavity when the device is turned off.

The technical result to be obtained from use of the present invention is that the device compared to the prototype due to the introduction of the inductor and an ultrasonic transducer makes it possible to carry out ultrasonic impact and influence of the magnetic field, which increases therapeutic efficacy.

Ultrasound can accelerate the resorption of swelling caused by damage to soft tissues, and stimulates physiological processes in the body [Demin YOU Pronchatov-Scars NV Modern acoustic research methods in biology and medicine. Educational-methodical material for the training program "Storage and processing of information in biological systems". - Nizhny Novgorod, 2007, 121 S.]. Ultrasonic vibrations carry out effective micro-massage of tissues and cells, improving tissue blood supply and lymph, increasing the permeability of cell membranes, accelerating the diffusion processes in the cells, stimulating tissue regeneration (accelerating the healing of wounds and trophic ulcers) [raigorodsky, Y.M. Ultrasonic technology in medical diagnosis and treatment // raigorodsky, Y.M., Liberzon D.M., Kurdin, Y.A., Poles I.I. Reviews on electronics. Ser. 7. Technology, organization of production and equipment. - 1984. - Issue 1. - 75].

The mechanism of action of the magnetic field leads to the normalization of physiological relationships between the various systems of the body by affecting the humoral (neurotransmitter) processes and biological membranes, wounds, pain relief by delay and distortion of nerve impulses from the source of pain [Samosyuk I.Z., Lysenok VP Acupuncture (Medical encyclopedia). -M.: ACT-PRESS BOOK, 2004. - 528], has a positive effect on the biochemistry of cells [raigorodsky, Y.M., Saranow J.V., author A.V. Foretical properties physical fields and devices for optimal fizioterapii urology, dentistry and ophthalmology. - Saratov: Publishing house of Sarat. University, 2000. -272 S.: ill.]

Thus, the present invention allows to increase therapeutic efficacy.

Device for influencing the prostate gland, containing a hollow cylindrical body with a beveled end for contacting its working end with the impact zone, located near the working end of the device, the source of laser irradiation, a heating element, a temperature sensor, an active electrode and an indifferent electrode, characterized in that it is equipped with an electronic unit, an inductor and a node of ultrasonic influence, representing a system with concentrator of ultrasonic vibrations, made in the form of a metal rod and at the same time being an active electrode at one end of the active electrode placed on the working face of the device, and a second end mechanically connected to the system and connected to the electronic module, the indifferent electrode is also connected to the electronic unit, is located outside the housing, and the inductor is designed so that the active electrode passes through its axis of symmetry, and the system aimed the laser light source, a heating element, a sensor and an inductor connected to the electronic module.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely medicine, and may be used for treating urethral syndrome in females with using the antibacterial preparation gentamycin. Gentamycin is introduced into a urethral wall in the amount of 80 mg dissolved in anaesthetic solution 2 ml. The above preparation is introduced in parallel with the urethral wall. The anaesthetic is presented by 0.25% Novocaine. That is followed by a vulvar exposure to an infrared laser light at wave length 0.82 mcm, frequency 3000 Hz, and power 10 mWt. A procedure length makes 5-6 minutes; the therapeutic course is 8-10 procedures.

EFFECT: method is well tolerated, accessible and high effective by providing the high gentamycin concentration in the area of inflammation and stimulating repair processes.

1 ex, 2 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, treating a cervical pathology associated with a high-oncogenicity human papilloma virus (HPV) infection. To eliminate the HPV for the purpose of the prevention of cervical cancer, a cervical mucosa is coated with a layer of a carbon dye and exposed to a laser light. What is used is a pulse-periodic generation mode having the following parameters: power flow density 2-10 J/cm2, radiation pulse duration 10-4 -10-2 sec, pulse repetition rate 1-5 Hz, wave length 0.8-1.1 mcm. A device for implementing the method comprises a laser working in the above mode with the above parameters, a modulator, a control and indication unit for laser parameter setting by the modulator, a parameter measurement unit for laser control, a controlled microinjector, a carbon dye delivery and radiation system actuated by the controlled microinjector, a probing laser for controlling the carbon dye layer thickness.

EFFECT: group of inventions provides eliminating the HPV from the cervical surface, controlling the thermal exposure area, its safety with avoiding an uncontrolled, irreversible injury of the cervical surface and the uterine itself.

8 cl, 1 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to ophthalmology. What is involved is a brachytherapy of an intraocular melanoma with a size of more than 6.5 mm by anchoring a beta-applicator with ruthenium-106 +rhodium-106 to an episclera for 7-14 days on a projection of the melanoma at total radiation dosage 3000 Gy. The brachytherapy is combined with a diode-laser transpupillar therapy of the melanoma at radiation power 800 mWt. Then, 6-12 months after the beta-applicator has been removed, a restrictive retinal coagulation at power 500 mWt and an endoresection of the residual melanoma follow. The method enables avoiding such complications, as vitreous body and retina haemorrhage, retinal detachment, complete loss of vision, as well as reducing a probability of metastases due to the preliminary brachytherapy and the following restrictive retinal laser coagulation.

EFFECT: combined application of the thermal therapy and brachytherapy enables affecting the melanoma from both sides for more complete destruction of its structure.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, physiotherapy. A method involves the integrated treatment of the patients with genital endometriosis and hysteromyoma. The treatment involves taking mineral water, observing a biologically programmed light pattern, taking radon baths and radon gynaecological irrigations and small enemas, as well as conducting a laser therapy of biologically active points (BAPs). The patients take carbonated chloride-hydrocarbonate-sulphate sodium-calcium warm Narzan water taken from sources No. 4, No. 7 and No. 24, 3.4 mg per kg 3 times ad day, 40 minutes before meals. The radon baths are taken with the radon concentration of 1.5 kBq/l. The radon gynaecological irrigations and microenemas are performed with the radon concentration of 6.5 kBq/l, temperature 36C, for 15 minutes within the course of 10-12 procedures. The BAP laser therapy is conducted in an autoresonant mode. The BAPs of anterior median meridian are covered, including: 1-2 (qu-gu), 1-3 (zhong-ji), 1-4 (guan-yuan), 1-5 (shi-men), 1-7 (yin-jiao); renal meridian: R-12 (da-ho), R-13 (qi-xu), R-14 (si-man), R-15 (zhong-zhu), R-16 (huang-shu); bladder meridian: V-31 (shang-liao), V-32 (ci-liao), V-33 (zhong-liao), V-34 (xia-liao); posterior median meridian: T-2 (yao-shu), T-3 (yao-yang-guan), T-4 (min-man), T-5 (xuan-shu). Using the radon baths of the different radon concentrations 'softens' an effect of the absorbed radiation dose on the homeostasis systems and preserves an effect of a high absorbed dose on the genital system. The laser therapy in the autoresonant mode within pathological BAPs improves the accuracy of the exposure on the pathological processes within a target organs.

EFFECT: method prolongs the remission, normalises the hormonal ratios in the remote period.

2 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to ophthalmology. That is ensured by the integrated treatment involving the single macular exposure to a sublimit micro-pulse infrared laser light. That is combined with the ozone therapy using drug preparations with underlying mixed gas agitation. That is followed by an antioxidant therapy consisting of local instillations of emixipin and oral administration of complivit oftalmo.

EFFECT: method enables the therapy of predisciform age-related macular degeneration at the stage of confluent drusens, preventing the development of the disease and improving the visual acuity.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and may be used in treating trophic ulcers and infected persistent wounds. That is ensured by the exposure to an argon plasma flow in a dose of 100-250 J/cm2 at 10-25 cm from the treated surface. The exposure length on one field makes 10-25 seconds. The sound surface treatment is followed by the dynamic exposure to a running argon plasma flow at 10-20 cm in a dose of 80-150 J/cm2 over the whole wound surface to form a gloss on the wound surface.

EFFECT: method provides the effective treatment of the given pathology ensured by specifying a mode of the exposure causing the microorganism elimination, wound surface drying, sudden perifocal oedema reduction, as well as epithelial cell growth stimulation on the periphery of the wound, as well as on its free surface.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. A method of treating the patients with the complicated forms of diabetic foot by blood sampling, centrifugation, plasma removal, erythrocyte fraction recovery, introduction of the angiotropic drug alprostadil, exposure to laser light at power 12 mWt for 20 minutes, addition of normal saline 100 ml in erythrocyte fraction 200 ml and reinfusion for 1.5-2 hours; ATP 2 ml is combined with the angiotropic drug alprostadil and introduced into the erythrocyte fraction; the erythrocyte fraction is reinfused every second day, alternated with intravenous drop-by-drop introduction of Vessel-DUE-F 600 LSU and actovegin 5 ml per normal saline 100 ml; the therapeutic course is 10 days.

EFFECT: using the method provides higher effectiveness and reduces the length of treatment of the patients with the complicated forms of diabetic foot syndrome, promotes the longer preservation of the achieved therapeutic effect.

FIELD: medicine.

SUBSTANCE: invention refers to medicine. Treating nosocomial sinusitis in resuscitation and intensive care units is ensured by nasal cavity clearance and sinus irrigation according to the common technique using a Kulikovsky's needle. The solution of polymyxin E in the concentration of 133 mcg/ml is introduced for 10 minutes before sinus administration of a photosensitiser that is methylene blue 20 ml in the concentration of 15 mcg/ml. The contents are aspirated with a syringe. The sinus mucosa is exposed to laser light through a dissipative light guide introduced through the Kulikovsky's needle at wave legnth 660 nm, power 500 mWt, emission length 23.5 minutes.

EFFECT: method enables enhancing the photodynamic effect on the gram-negative microorganisms ensured by including polymyxin E relieving the photosensitiser adhesion on the surface of a gram-negative bacterial cell into the method of the photodynamic therapy.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to physiotherapy, urology. A method involves the integrated physiotherapeutic effect of three physical factors. The ultrasonic exposure is characterised by frequency 2.7 kHz + 0.2 kHz, length 9 ms, pulse period 200 ms. The exposure to magnetic field is characterised by magnetic induction amplitude 1300 mT, pulse period 80 ms. The laser exposure is characterised by power 5.0 Wt, frequency 80 Hz. Total duration of a procedure is 30 minutes.

EFFECT: due to using the sequential effect of three physical factors, the method reduces the period of small urolith evacuation, the intensity of pain syndrome, requirement in analgesic and anti-spasmodic drugs, minimises the development of sclerotic changes in the ureter wall that improves urinary outflow and reduces a risk of recurrent urolith formation.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to neurology. The method involves the integrated treatment. Azathioprine, dexamethasone and analgin are administered into the patient. Azathioprine 50 mg is administered three times a day, after meals for 21 days. Dexamethasone 4 mg is administered intramuscularly three times a day for 15 days. From the 16th to 18th day of treatment, dexamethasone 4 mg is administered 2 times a day - in the morning and afternoon. From the 19th to 20th day, the same is administered in a dose of 4 mg in the afternoon. Before bedtime, 50% analgin 2.0 ml is administered parenterally for 10 days. At 9 o'clock in the morning, patient's lumbar pain area is exposed to the magnetic laser treatment. The patient is exposed to infrared light of wave length 0.8-0.9 mcm, pulse power 5-8 Wt, pulse frequency 1000 Hz and magnetic strength 35 mT. The exposure is contact and stable, and covers the fields paravertebrally. The length of the one-field exposure is 2 minutes. The therapeutic course is 15 procedures. Trives spinal assistant is put on in the horizontal position of lying on back. The spinal assistant is taken off in the horizontal position before bedtime.

EFFECT: method reduces the length of treatment, prolongs a remission, including due to the developed modes and combinations of the various components of the exposure.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!